DBP starts delivering Pileseptin to Norway
Double Bond Pharmaceuticals subsidiary Drugsson has now started delivering Pileseptin to Fyrstikktorget pharmacy in Norway.
"As a step towards growth and development of Drugsson we have now started to expand our sales to other Nordic countries", comments Igor Lokot, CEO of Double Bond Pharma and Drugsson AB.
More about Fyrstikktorget apotek: www.apotekhjem.no
More about Pileseptin: It's a new treatment for hemorrhoids that works effectively by reducing swelling and keeping the area clean from bacteria and dirt. Pileseptin Spray is used against external hemorrhoids and Pileseptin Gel against internal hemorrhoids. Pileseptin is the only product of its kind to abaite hemorrhoids and not just the symptoms. www.pileseptin.se
More about Drugsson AB: www.drugsson.com
For more info, contact
Igor Lokot, CEO
Information on Double Bond Pharmaceutical International AB
DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline. DBP has during the past year also started two subsidiaries, Drugsson AB for the distribution of fully developed human pharmaceutical and medical device products and dietary supplements in Scandinavia, and FarmPharma AB for the development of innovative veterinary products.